LONDON and NEW YORK, Sept. 9, 2026 /PRNewswire/ -- ION, a global leader in trading and workflow automation software, high-value analytics and insights, and strategic consulting to financial institutions, central banks, governments, and corporates, announces that Coinbase has selected ION's XTP for Event Contracts to support event contract clearing for Kalshi, the world's largest prediction market.

Event Contracts is ION's latest extension to its flagship XTP solution, offering a fully automated, real-time platform for the creation, resolution, and settlement of event-based contracts. It provides Coinbase with the ability to confidently support execution and processing of event contracts in real-time with minimal impact to existing operational processes while supporting real-time contract design capability, onboarding of tens of thousands of accounts per day, and fully automated 24/7 processing.

ION and Coinbase partnered to support Kalshi's listing of event contracts in December 2025. XTP's modern architecture has enabled the adoption of an accelerated deployment timeframe through three-way collaboration between ION, Coinbase and Kalshi, who worked to expedite analysis, development, and rollout. During the initial rollout, XTP demonstrated its ability to support high-volume activity for Kalshi, including processing its first one million trades over Super Bowl weekend.

XTP for Event Contracts provides Futures Commission Merchants (FCMs) with a unique opportunity to run event contracts alongside existing ETD and cOTC business in a single solution, thanks to native reporting, automated settlement, and multiexchange connectivity. The result is fast onboarding, low operational lift, and seamless scaling as the volume grows. Already relied upon by leading FCMs, XTP now brings the same robustness and real-time processing to the fast-growing prediction market sector.

Toni Gemayel, Head of Prediction Markets at Coinbase, said: "Partnering with ION provides the operational infrastructure needed to support our expanding event contracts business. XTP's real-time processing capability allows us to manage growing prediction market volumes while maintaining the back-office stability and execution standards."

Max Crowley, Vice President of Business Development at Kalshi, said: "We're excited that XTP can support Kalshi and Coinbase FCM in this offering. Safe and regulated markets require not only strong exchange rules and oversight, but also sound operational risk management and processing such as that provided by XTP."

Samuel Shorthouse, Head of Client Engagement, Cleared Derivatives at ION, said: "We are pleased to partner with Coinbase and Kalshi as they expand access to regulated event‑based markets at a time when this sector is evolving rapidly. Deploying XTP to support these workflows provides a robust and trusted foundation with real‑time capabilities that help clients manage their activity effectively. This collaboration reflects our commitment to supporting the growth of this emerging market in a secure, scalable, and sustainable way."

About ION

ION provides mission-critical trading and workflow automation software, high-value analytics and insights, and strategic consulting to financial institutions, central banks, governments, and corporates. Our solutions and services simplify complex processes, boost efficiency, and enable better decision-making. We build long-term partnerships with our clients, helping transform their businesses for sustained success through continuous innovation. For more information, visit https://iongroup.com/.

About Coinbase Inc.

Coinbase (NASDAQ: COIN) is on a mission to increase economic freedom in the world. The most trusted crypto platform, Coinbase stores more digital assets than any other company and is building the everything exchange — one place to access crypto, equities, derivatives, prediction markets, and more. Coinbase serves consumers through its suite of financial apps, institutions through Coinbase Prime, and developers through the Coinbase Developer Platform. Coinbase's full-stack platform was purpose-built to power the future of finance: secure custody, deep exchange liquidity, stablecoin infrastructure, and global settlement rails — all built on a decade-plus foundation of security and compliance.

About Kalshi

Founded in 2018, Kalshi is the world's next-generation financial exchange. Prediction markets provide accurate, real-time information on the likelihood of events, making humanity more informed about the future. As the first regulated exchange for events, Kalshi is credited with legalizing and establishing prediction markets as a financial asset class. It's the leading safe and regulated platform, trusted by millions of people and a growing number of institutions in America. To learn more about Kalshi, visit www.kalshi.com.

All product and company names herein may be trademarks of their registered owners.

SOURCE ION

Share this article

BOULDER, Colo., Sept. 9, 2026 /PRNewswire/ -- Integral Consulting Inc., a leading environmental science and engineering consulting firm, today announced its acquisition of Heritage Environmental Consultants, a Western U.S. based provider of environmental planning, permitting, and scientific services to industry and government clients.

Heritage Environmental Consultants brings expertise across wildlife biology, terrestrial and aquatic ecology, soil science, hydrology, water and air quality, and geographic information systems. The acquisition brings together two multidisciplinary firms who provide clients with more integrated solutions that combine environmental planning, permitting, ecological sciences, regulatory expertise, and technical consulting to projects from early development through implementation and long-term compliance.

"Heritage strengthens our ability to deliver services where thoughtful planning and effective permitting strategies can have the greatest impact on project success," said Ryan Brain, CEO of Integral Consulting. "Their expertise complements Integral's existing capabilities and deepens our ability to provide integrated solutions across the full project life cycle."

"Joining Integral creates exciting opportunities for both our clients and our employees," said Patrick Golden, Founder and President of Heritage Environmental Consultants. "We share a common commitment to scientific rigor, responsiveness, and helping clients solve complex environmental challenges. Together, we can bring broader expertise, greater resources, and expanded geographic reach to the projects and communities we serve."

The acquisition strengthens Integral's position in the Mountain West and expands the firm's ability to deliver for clients by navigating complex environmental and regulatory requirements associated with energy, mining, infrastructure, and natural resource development projects.

About Integral Consulting Inc.

At Integral, we deliver results for clients to make informed, strategic, and compliant decisions involving the environment and human health. Our team of scientists, engineers, and regulatory specialists cuts through complexity and keeps projects moving toward trusted, practical, and lasting outcomes.

About Heritage Environmental Consultants

Founded in 2008, Heritage Environmental Consultants provides environmental planning, permitting, and scientific services to industry and government clients throughout the western United States. The firm's multidisciplinary expertise spans ecology, hydrology, water and air quality, GIS, and environmental compliance, helping clients successfully navigate environmental review and permitting requirements.

Zach Gostanian, [email protected]

SOURCE Integral Consulting Inc.

Share this article

PETACH TIKVA, Israel, Sept. 9, 2026 /PRNewswire/ -- Eltek Ltd. (NASDAQ: ELTK), a leading global manufacturer of high-quality printed circuit boards, today announced that Mr. Eli Yaffe, Chief Executive Officer of the Company, has informed the Board of Directors (the "Board") of his decision to retire from his position as Chief Executive Officer, effective September 23, 2026. Mr. Yaffe will continue to serve as CEO until that date, to ensure an orderly transition of his role to Ron Freund, the Company's current Chief Financial Officer, who has been appointed by the Board as Chief Executive Officer, effective September 23, 2026. Mr. Freund will continue to serve as the Company's Chief Financial Officer until a new Chief Financial Officer is appointed.

Board Appreciation and Recognition

The Board of Directors wishes to express its deep gratitude and sincere appreciation to Mr. Yaffe for his exceptional leadership, unwavering dedication, and outstanding contributions to the Company during his tenure as Chief Executive Officer since July 2018. Under Mr. Yaffe's stewardship, Eltek has achieved significant milestones and has strengthened its position as a leader in the high-end printed circuit board market.

Mr. Yitzhak Nissan, Chairman of the Board of Directors, stated: "On behalf of the entire Board, I want to extend our heartfelt thanks to Eli for his remarkable leadership over the past eight years. Eli joined Eltek at a critical juncture and has since transformed the Company into a stronger, more competitive, and more technologically advanced organization. His strategic vision and tireless efforts have driven meaningful growth and positioned Eltek for continued success. We are deeply grateful for his service and dedication."

Appointment as Director

In recognition of his extensive experience and deep knowledge of the Company's business and operations, the Board has resolved to appoint Mr. Yaffe as a director of the Company, effective March 8, 2027. Such appointment shall continue until the next annual general meeting of the Company. Mr. Eli Yaffe, aged 71, has served as Chief Executive Officer of the Company since July 2018. Prior to joining Eltek, Mr. Yaffe served as President of Carmel Forge Ltd. (Aerospace) for almost 16 years, President of Urdan Industries Ltd. (Defense), and Vice President of Business Development & Strategic Planning at Ormat Industries Ltd. Mr. Yaffe holds a B.Sc. (with distinction) from the Technion-Israel Institute of Technology, an M.Sc. in Mechanical Engineering from Tel Aviv University, and an MBA (with distinction) in Finance & Marketing from Bar Ilan University.

Appointment of Chief Executive Officer

The Board has appointed Mr. Ron Freund, the Company's Chief Financial Officer, as Chief Executive Officer of the Company, effective September 23, 2026. Mr. Freund will continue to serve as the Company's Chief Financial Officer until a new Chief Financial Officer is appointed.

Mr. Ron Freund, aged 62, has served as the Chief Financial Officer of the Company since January 2022 and prior to that served as the CFO of Ophir Tours Ltd. from 2015 to 2021. Mr. Freund is a seasoned finance and business executive with more than 30 years of experience in financial management, capital markets, corporate strategy and business operations, including extensive experience with public companies listed on NASDAQ and the Tel Aviv Stock Exchange. Mr. Freund holds a B.A. degree in Accounting and Economics from the Hebrew University of Jerusalem and is a licensed CPA (Israel).

Mr. Yitzhak Nissan, Chairman of the Board of Directors, stated: "We are pleased to appoint Ron Freund as the Company's CEO. Ron brings extensive experience, a deep understanding of the Company and its operations, and a strong commitment to its continued success. We are confident that he will make a significant contribution to the Company as it continues to execute its strategy and pursue its growth opportunities. On behalf of the Board of Directors, I would like to congratulate Ron on his appointment and wish him every success in his new role."

About Eltek

Eltek – "Innovation Across the Board", is a global manufacturer and supplier of technologically advanced solutions in the field of printed circuit boards (PCBs) and is an Israeli leading company in this industry. PCBs are the core circuitry of most electronic devices. Eltek specializes in the manufacture and supply of complex and high-quality PCBs, HDI, multilayered and flex-rigid boards for the high-end market. Eltek is ITAR compliant and has AS-9100 and NADCAP Electronics certifications. Its customers include leading companies in the defense, aerospace and medical industries in Israel, the United States, Europe and Asia.

Eltek was founded in 1970. The Company's headquarters, R&D, production and marketing center are located in Israel. Eltek also operates through its subsidiary in North America and by agents and distributors in Europe, India, South Africa and South America.

For more information, visit Eltek's web site at www.nisteceltek.com

Forward Looking Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties including, but not limited to expected results in future quarters, the impact of currency movements between the US Dollar exchange rate against the Israeli Shekel, the impact of the Coronavirus on the economy and our operations, risks in product and technology development and rapid technological change, product demand, the impact of competitive products and pricing, market acceptance, the sales cycle, changing economic conditions and other risk factors detailed in the Company's Annual Report on Form 20-F and other filings with the United States Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Investor Contact

Ron Freund

Chief Financial Officer

[email protected] 

+972-3-939-5023

SOURCE Eltek Ltd.

Share this article

VANCOUVER, BC, Sept. 9, 2026 /PRNewswire/ -- OceanaGold Corporation (TSX: OGC, NYSE: OGC) ("OceanaGold" or the "Company") announces that it has lodged its application for approval of the Macraes Phase 4 Project ("MP4") under New Zealand's Fast-track Approvals Act 2024. The MP4 application seeks to extend the mine life at Macraes from the current reserve life of 2032 to the late 2030s, consistent with Macraes' history of mine life extension since it commenced operation in 1990.

The Company also provides details on the technical study work and exploration results which support the potential to extend mine life at Macraes via MP4 and beyond.

Gerard Bond, President and CEO of OceanaGold, said "Submitting the MP4 application is an important step in securing the long-term future of Macraes through permitting of additional open pit cutbacks and a mine life extension to the late 2030s. Recent drilling supports both the extensions included in MP4 and identifies further opportunities to potentially enable meaningful gold production into the 2040s.

For 36 years Macraes has safely and responsibly produced gold, delivering multi-generational benefits to the surrounding communities and to New Zealand through sustaining many hundreds of jobs, socio-economic community contributions, taxes and royalties, and export earnings. Our permit application and exploration results show the potential for Macraes to continue its long history of value creation while generating strong returns for our stakeholders."

For a visual overview of the site, mine life extension opportunities and drill results, please see the accompanying 3D video:

Macraes is located on the South Island of New Zealand, approximately 60 kilometres ("km") northwest of Dunedin. Production at Macraes commenced in 1990, with an initial 7-year mine life. In July of this year, the mine celebrated the production of its 6 millionth ounce of gold over its 36-year operating history. Macraes has a geologically prospective land package of over 14,000 hectares, including a 30 km highly mineralized structure known as the Macraes Shear Zone which hosts multiple gold deposits and exploration targets (Figure 1).

Macraes Mine Life Extension Potential

MP4 Fast-track Application

On September 9, 2026, the Company lodged its Fast-track application for the MP4 project. The MP4 application includes:

permitting for all activities required to complete the current reserve mine plan;

the development of Southern Pit Innes Mills ("SPIM", details below);

extensions of the Golden Point Underground ("GPUG"); and

flexibility to incorporate additional Mineral Resources into the future production profile.

Approval of MP4 will enable the extension of the Macraes operation to the late 2030s. Under the "one-stop shop" process of the New Zealand government, the Company expects MP4 to be fully permitted by mid-2027 (subject to appeals). MP4 permit approval is necessary for mine life extension, subject to achieving other ancillary permits, satisfactory technical and financial reviews, and market and operating conditions.

Approval and subsequent execution of MP4 works will enable the Macraes operation to continue to have a strong positive impact on the Otago region and New Zealand more broadly for many more years, bringing substantial investment, maintaining current and future employment opportunities and continuing to provide meaningful social, environmental and economic benefits.

The Company is familiar with the Fast-track approval process, having successfully permitted the Waihi North Project in 2025.

Mine Life Extension Technical Studies

The approval of MP4 will enable the Company to proceed with extensions to the Innes Mills, Coronation, Coronation North and Golden Bar open pits. A mine life extension of Golden Point Underground is also included in MP4, to provide additional flexibility for future development.

MP4 also includes an extension to the north of the current Innes Mills open pit, referred to as SPIM. Advanced studies are underway to bring SPIM into Mineral Resources by year end 2026, supported by drilling completed in prior years.

The Company believes that SPIM has the capability to contribute meaningful production at Macraes from 2032. Together with the extension of the Golden Point Underground, the Company is targeting to maintain production at Macraes above 100,000 ounces per year into the late 2030s.

Details regarding Macraes' expected production profile, development timeline for SPIM, capital expenditures and overall economics will be included in an updated National Instrument – 43-101 Standards of Disclosure for Mineral Projects ("NI 43-101") technical report that is expected to be released in early 2028.

SPIM development capital will include waste stripping, rehandling and relocation of a portion of historic tailings into the current Frasers tailings storage facility, relocation of the open pit workshop, re-routing the public road, and upgrades to site power infrastructure.

Advancing SPIM also has the benefit of enhancing the feasibility of mining the Round Hill deposit which was previously removed from Mineral Resources at year-end 2023. The Round Hill deposit is not included in MP4 and represents a potential opportunity for mine life extension into the 2040s.

Macraes Exploration Overview

The 2026 exploration program at Macraes is focused on supporting the mine life extensions outlined in MP4 and beyond. Supported by a record expected expenditure of US$13 million in 2026, a total of 60,000 metres ("m") of drilling is being executed at Macraes. The Innes Mills, Coronation and Nunns open pits, together with Golden Point Underground, continue to show significant potential for further resource conversion and growth.

Macraes Drill Results

Innes Mills

Innes Mills has been the main open pit ore source since 2024, accounting for approximately 39% of total Measured and Indicated Mineral Resource ounces for Macraes as at December 31, 2025. Drilling since the last resource estimate has focused on conversion of Inferred Mineral Resources in, and down dip of, the current reserve open pit design, with more than 12,000 m across 48 holes completed (Table 1). Drill hole DDH8224 returned 25.0 m @ 0.8 g/t gold ("Au"), confirming that mineralization continues at least 150 m down dip, towards the east, beyond the Innes Mills current reserve open pit design (Figure 2). This area is a target for additional resource expansion drilling in the remainder of this year to confirm the economic feasibility of additional future open pit cutbacks.

Golden Point Underground (GPUG)

GPUG is located immediately down dip of the historic Golden Point and Round Hill open pits which were mined between 1990 and 2002 and produced approximately 1.3 million ounces of gold. Underground mining at GPUG commenced in 2021.

Since the last resource estimate for the year ended December 31, 2025, more than 13,000 m of drilling across 37 holes has been completed, targeting both conversion and extension opportunities (Table 1).

In the north, DDH8281 stepped out approximately 40 m down dip of the current mine plan, intercepting 12.0 m @ 2.1 g/t Au and confirming the continuation of economic mineralization down-plunge. In the south, a 40 m step-out from the existing mine plan reported 15.0 m @ 1.5 g/t Au (DDH8412). These results are well above the current underground reserve cut-off grade and support the potential for future resource and reserve growth to the east and southeast (Figure 3). Drilling will continue at GPUG for the remainder of the year, targeting extension to mineralization both down dip and to the south along strike, where the deposit remains open, to further grow the resource.

Coronation

The Coronation open pit is located approximately 5 km to the northeast of the processing plant. Since the last resource estimate, more than 6,000 m of drilling across 36 holes has been completed at Coronation, with a focus on the conversion of Inferred Mineral Resources (Table 1).

Notable results included 7.9 m @ 5.4 g/t Au (DDH8286), 12.0 m @ 2.3 g/t Au (DDH8298), 21.0 m @ 1.1 g/t Au (DDH8283) and 6.0 m @ 1.7 g/t Au (DDH8367), which support the emergence of a higher-grade zone plunging to the southeast (Figure 4). This area remains open to the southeast, with further exploration drilling planned to pursue extension of this higher-grade trend beyond the current pit design to support future pit cutbacks.

Nunns

The Nunns prospect, containing a small resource defined in 2017, is located at the northwestern end of the Macraes property, approximately 6 km along strike from Coronation. Following the Company's additional land purchase in early 2026, a drill program focused on converting and growing the existing Mineral Resources, with 4,250 m of drilling across 48 drill holes was completed (Table 1). Notable results included 14.0 m @ 2.5 g/t Au (RCH8374), 8.0 m @ 4.2 g/t Au (RCH8375) and 4.0 m @ 7.9 g/t Au (RCH8344), confirming the extension of mineralization down dip and along strike, outside of the known resource (refer to VRIFY).

The mineralization at Nunns represents a potentially low capital, future open pit ore source for Macraes, that is outside of the MP4 permit application. An updated resource estimate is expected to be included at the end of 2026.

Table 1: Select Macraes significant drill intersections since the 2025 resource estimate[1]

OceanaGold is a global intermediate gold and copper producer committed to safely and responsibly maximizing the generation of Free Cash Flow from our operations and delivering strong returns for our shareholders. We have a portfolio of four operating mines: the wholly-owned Haile Gold Mine in the United States of America; the wholly-owned Macraes and Waihi operations in New Zealand; and the 80%-owned Didipio Mine in the Philippines.

TUCSON, Ariz., Sept. 9, 2026 /PRNewswire/ -- As blood programs expand across hospitals, blood centers, EMS agencies, air medical providers, and statewide networks, organizations face a common challenge: how to maintain complete visibility, compliance, and accountability without increasing administrative complexity. Delta Development Team developed BloodCOMM® to solve that challenge.

BloodCOMM® is an intelligent, cloud-based blood management platform that digitizes and automates the blood supply chain, creating a connected ecosystem that enables organizations to track blood units from collection through disposition. By combining AI-assisted scanning, automated workflows, real-time monitoring, GPS-enabled asset visibility, and unit-level cold chain intelligence, BloodCOMM® transforms blood management from a fragmented operational process into a fully connected digital infrastructure.

Recent research examining prehospital trauma care found that once the type and number of interventions delivered on scene were taken into account, prehospital time alone was no longer independently associated with mortality. The findings underscore that the value of the "golden hour" lies not simply in minimizing time, but in using that time to deliver the right interventions. Hemorrhage-control measures were associated with significantly better survival outcomes, reinforcing the importance of timely, effective care. In time-sensitive environments, reducing the administrative burden surrounding blood management can help teams spend less time searching for information, documenting events, and coordinating handoffs—and more time focused on operational readiness and patient care.

Bringing Intelligence to Every Unit of Blood

At the heart of BloodCOMM® is a simple concept: every unit needs to be accounted for.

Through barcode scanning, AI-powered label recognition, and automated event tracking, BloodCOMM® creates a digital identity for each blood unit, enabling organizations to continuously monitor location, temperature, expiration status, inspections, transfers, excursions, and final disposition throughout its lifecycle.

The result is a complete digital cold chain of custody that provides end-to-end visibility into blood movement and handling. Every documented interaction contributes to a comprehensive digital record that authorized stakeholders can access when needed. Relevant patient identifiers, product and disposition details, and deviation history are captured as events occur rather than reconstructed afterward from disconnected records.

From Manual Oversight to Intelligent Automation

Historically, blood program management has relied on paper logs, spreadsheets, manual reporting, and labor-intensive tracking processes. BloodCOMM® replaces those disconnected workflows with intelligent automation.

The platform automatically records chain-of-custody events, detects and documents temperature excursions, generates alerts, tracks inspections, and assembles detailed blood unit histories without requiring manual data collection. When a unit is transfused or returned, configured alerts can notify relevant program participants, while comprehensive PDF reports can be easily shared with external stakeholders when needed.

By automating routine administrative tasks, organizations can reduce workload, improve operational efficiency, strengthen compliance, and allow clinical teams to focus on patient care rather than paperwork. Because blood program records may need to be retained for years depending on the record type, and transfusion events require thorough review, that history needs to be complete and retrievable, not assembled under pressure ahead of an audit. The same dashboards and analytics that support this automation also give administrators visibility into blood utilization, inventory trends, expiration management, and program performance. These insights can help organizations reduce waste, support funding initiatives, and make more informed operational decisions.

A Connected Network, Visible in Real Time

Unlike traditional monitoring solutions that focus primarily on refrigeration equipment temperature, BloodCOMM® was designed to serve as the digital backbone of DDT's comprehensive blood management ecosystem. The system connects blood units, smart storage devices, blood banks, hospitals, EMS agencies, air medical programs, and regional leadership through a single cloud-based environment, with premium-enabled devices adding GPS tracking so organizations can monitor enrolled devices and their blood products throughout transportation, deployment, and storage.

As EMS blood programs formalize dedicated coordinator roles to manage this complexity, as outlined in a recent framework published in Trauma Surgery & Acute Care Open, having one unified system across devices and participating agencies can reduce variability instead of adding another layer of information to reconcile.

This unified approach enables organizations to move beyond isolated blood management practices and toward a coordinated, data-driven model that supports collaboration across entire healthcare networks.

More than software, BloodCOMM is the digital infrastructure that enables blood programs, from individual hospitals and EMS agencies to regional and statewide networks, to scale confidently while maintaining accountability and traceability.

About Delta Development Team

Delta Development Team (DDT) is a U.S.-based medical technology company headquartered in Tucson, Arizona, specializing in prehospital blood storage and transfusion solutions for emergency medical services, hospitals, and military medical teams. Its integrated ecosystem, including the APRU 6L Portable Blood Refrigerator, Delta ICE 2L Smart Blood Cooler, and BloodCOMM® blood management software platform, helps first responders and clinical teams maintain cold chain compliance, accountability, and operational readiness from blood bank to point of care. For more information, visit deltadevteam.com or contact [email protected].

SOURCE Delta Development Team

Share this article

SUMMIT, N.J. and NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Taproot Capital ("Taproot"), an alternative asset manager specializing in seeding first-time funds and partnering with emerging and growing private equity firms, today announced that Harry Bromley-Davenport has joined the firm as a Partner. In this role, Mr. Bromley-Davenport will focus on capital raising efforts for Taproot's portfolio funds as well as cultivating and strengthening relationships with prospective investors across the United States.

Mr. Bromley-Davenport will further strengthen Taproot's investor engagement capabilities, bringing more than a decade of private markets experience to the firm. He joins Taproot from Rede Partners, where he served as Director and a senior member of the Americas Coverage team. Throughout his career, Mr. Bromley-Davenport has partnered with private equity and alternative investment managers to deploy capital on behalf of UHNW clients, pension funds & corporates, as well as provide strategic guidance, lead capital formation, and deliver primary fund solutions to institutional investors and sponsors alike.

"All four co-founding partners at Taproot are thrilled to welcome Harry to the partnership team," said Eric Zoller, CEO and Co-Founder of Taproot. "Harry brings deep relationships across the industry and a track record of collaborating with clients to develop and execute fundraising strategies, experience that will further enhance how we partner with founders and support their growth. We're excited for Harry to play an important role as we scale the business and continue to build on the value we provide to our portfolio funds."

"Taproot has built a differentiated platform that combines its expertise in firm building with a true partnership approach, providing founders with the strategic guidance and resources required to launch and scale successful firms," said Mr. Bromley-Davenport. "I look forward to continuing my work with the institutional investor community I have served to expand the firm's and our portfolio funds' market presence and help drive continued growth."

Mr. Bromley-Davenport received First Class Honor's from Bristol University. He holds the FINRA Series 7 and Series 63 registrations in the United States and has passed the Securities Industry Essentials (SIE) examination. In the United Kingdom, he holds the CISI Level 7 qualification and the Investment Advice Diploma.

About Taproot Capital

Taproot Capital is an alternative asset manager specializing in seeding first-time funds and partnering with emerging and growing private equity firms. Led by the firm's co-founders, Eric Zoller, Matthew Thornton, Bobby Farina and Kristy Hogan, Taproot Capital delivers tailored capital solutions designed to support managers as they launch new strategies, institutionalize their operations, and scale their platforms. Taproot also provides limited partners with exposure to the emerging manager asset class through a customized private equity seeding lens. For more information, please visit https://taprootcap.com. Follow us on LinkedIn.

Taproot Capital Media Contact

Meghan Hazen

[email protected]

SOURCE Taproot Capital

Share this article

/C O R R E C T I O N -- Panasonic Connect Europe/

In the news release, "Improved colour matching functionality, new KAIROS control options, and standard-setting PTZ cameras reflect Panasonic's continuous broadcast innovation," issued on 03-Sep-2026 by Panasonic Connect Europe over PR Newswire, the subheading was incorrectly transmitted and distributed as the headline by PR Newswire. The complete, corrected release follows:

PANASONIC ENHANCES BROADCAST WORKFLOWS FROM CAMERA TO CONTROL ROOM

Improved colour matching functionality; new KAIROS control options; and standard-setting PTZ cameras reflect Panasonic's continuous broadcast innovation.

WIESBADEN, Germany, Sept. 9, 2026 /PRNewswire/ -- Panasonic Connect Europe's latest broadcast and ProAV innovations enable content creators and production teams to deliver smarter, more efficient and visually compelling live productions through advances in imaging, automation and workflow technology.

Enhanced KAIROS Control Panels

Panasonic has launched two new control panels for its KAIROS IT/IP live video production platform. These are available with 12 Buses/40 Crosspoint Buttons; and 12 Buses/30 Crosspoint Buttons, ideal for managing complex, large-scale live productions[1]. The large touch panels on each Bus row provide simple access to snapshots, macros, and other frequently used functions. This reduces operator fatigue and enables smoother switching. The AT-KP340 will be available in Q2 CY2027, with the AT-KP330 available in Q3 CY2027[2].

New Auto Colour-Matching for Image Adjust Pro Software

Panasonic's Image Adjust Pro Media Production Suite plug-in has been updated with enhanced virtual remote-control panels, and a new automatic colour-matching function. This automatically aligns the colours from multiple cameras to a reference camera without requiring specialist knowledge[3]. This reduces manual efforts to adjust gamma, matrix and colour correction settings, streamlining on-location colour matching.

This simplifies pre-production setup and reduces operator workload, while the intuitive GUI interface enables consistent colour matching across Panasonic and third-party cameras[4]. The result is a smarter, more efficient workflow for live production environments. The update is scheduled to be released in Q4 CY2026[5][6]. It is also planned to support the new AW-UE200 and AW-UER200 PTZ cameras in the future.

Enhanced Colour Adjustment for 4K Cameras

Panasonic has introduced new colour adjustment functions[7] for its AK-UCX100 studio camera, and AK-UBX100 multi-purpose camera, available in Q4 CY2026. These deliver the desired colour expression for creators, and simplify colour matching between cameras for live events with LED walls, broadcast studios, and virtual productions.

The Color Temp. Blend function takes the colour temperature data from LED walls and stage lighting, blending them to generate an optimal white balance for the desired shooting environment. This closely aligns visuals from real-world subjects and LED wall footage.

Target Color Correction allows users to designate a specific colour and adjust its hue and saturation individually. For example, it enables pinpoint correction of corporate brand colours or sponsor logos displayed on an LED wall. The function can configure up to three colour tables simultaneously.

Panasonic's Chroma Suppression function allows users to maintain overall colour reproduction whilst suppressing colour shift and saturation in highly saturated visuals. This is useful for operators shooting LED displays that feature vivid computer-generated imagery at live events such as concerts, whilst achieving high-quality video expression.

[1] Some features are still under development, so specifications and release dates are subject to change.

[2] For the latest information on product availability, please refer to the product website.

[3] Some features are still under development, so specifications, screens, supported models and release dates are subject to change.

[4] Only Panasonic cameras support colour adjustment using a reference camera, but the reference camera can be a third-party model.

[5] For the latest information on firmware availability, please refer to the product website.

[6] Automatic colour matching is available on models compatible with Image Adjust Pro (AW-SF600).

[7] Will be launched via firmware update.

Share this article

- If approved, MOGENRY would be the first gene-agnostic treatment available for patients with retinitis pigmentosa having severe vision loss

- BLA supported by positive RESTORE Phase 2b/3 data and REMAIN long-term follow-up data

DALLAS, Sept. 9, 2026 /PRNewswire/ -- Nanoscope Therapeutics, Inc. ("Nanoscope"), a biotechnology company focused on developing and commercializing novel, disease‑agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed the Biologics License Application (BLA) seeking approval of MOGENRY® (sonpiretigene isteparvovec, MCO-010), an optogenetic gene therapy designed for vision restoration for patients with retinitis pigmentosa (RP) having severe vision loss.

"FDA acceptance and filing of our BLA for MOGENRY is a crucial milestone that brings us a critical step closer to offering a one-time, in-office treatment option to the retinitis pigmentosa community with severe vision loss, who have no approved therapy today," said Sulagna Bhattacharya, Chief Executive Officer of Nanoscope Therapeutics. "The strength of our RESTORE data, together with the durability we have observed through long-term follow-up in the REMAIN study, give us confidence in MOGENRY's potential to become a new standard of care for patients living with RP having severe vision loss. We look forward to working closely with the FDA throughout its review."

The BLA is supported by positive efficacy and safety data from the Phase 1/2a trial (NCT04919473), and the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial (NCT04945772). RESTORE met its primary and key secondary endpoints, demonstrating improvements in visual acuity at weeks 52 and 76. MOGENRY was well tolerated, with no treatment-related serious adverse events reported.

"Restoring vision is the most challenging metric to achieve in ophthalmic gene therapy — and MOGENRY seems to be clearing that bar, with years of improved vision alongside it. That combination makes this a milestone moment, not just for our patients with an unmet need and Nanoscope, but for our entire field. MOGENRY does not require genetic testing or administration in a surgical suite, which could enable broad adoption by community retina practices. If approved, MOGENRY could usher in a new era of RP treatment within reach of patients who do not have access to a tertiary academic center," said Allen C. Ho, M.D., Professor of Ophthalmology, Thomas Jefferson University and Director of Retina Research, Wills Eye Hospital, and Chief Medical Advisor for Nanoscope Therapeutics.

Most patients dosed in RESTORE have continued into the REMAIN study, which provides long-term follow-up data in the BLA. If approved, MOGENRY would become the first gene-agnostic therapy to improve vision in patients with RP having severe vision loss.

"As retina specialists, we've watched plenty of promising drug candidates fail to show, let alone sustain, benefits for patients. What sets MOGENRY apart is a meaningful benefit, with evidence of sustained effect for years. Long-term durability is exactly what physicians need to see in a one-time treatment and know their patients can truly rely on it," said SriniVas Sadda, M.D., A. Ray Irvine, Jr., MD, Endowed Chair in Clinical Ophthalmology and Professor at the University of California, Los Angeles David Geffen School of Medicine and the Doheny Eye Institute, and Chair of Nanoscope's Visionary Advisory Committee.

About Retinitis Pigmentosa

Retinitis pigmentosa (RP) is a group of rare inherited disorders in which photoreceptor cells degenerate progressively, leading to impaired vision and eventual blindness. RP is linked to more than 1,000 mutations in over 100 genes. It is one of the leading causes of blindness among the working-age population in the U.S., affecting more than 100,000 people, of whom over 25,000 are legally blind. The rate of vision loss varies with the underlying mutation, but patients lose approximately 0.03 LogMAR — about 1.5 letters — per year on average, equivalent to roughly one line of vision on an eye chart every three years. A majority are legally blind (worse than 20/200) by the age of 60.

About MOGENRY (sonpiretigene isteparvovec, MCO-010)

Nanoscope's multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope's Co-Founder, President and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team has spent over a decade evaluating its performance across multiple animal models and human diseases. MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope's MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows.

About Nanoscope Therapeutics

Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the FDA has accepted and filed the Company's BLA for MOGENRY. If approved, MOGENRY has the potential to become the standard of care for patients with RP, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with RMAT designation for SD, and EMA Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has also received Sakigake and Orphan designations for inherited retinal dystrophies (IRDs) in Japan and an Orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in geographic atrophy is expected to start in 2026, and other IND-ready programs include Leber congenital amaurosis (LCA).

Media

Nanoscope Therapeutics, Inc.

(817) 857-1186

[email protected]

SOURCE Nanoscope Therapeutics

Share this article

Toronto and Tampa based firm also recognized as a Leader in Lead Generation, based entirely on verified customer reviews

TORONTO and TAMPA, Fla., Sept. 9, 2026 /PRNewswire/ -- The Sales Factory, a leading provider of outsourced sales and lead generation services, announced today that it has been named a Leader in G2's Summer 2026 Grid® Reports, ranking #2 globally in the Outsourced Sales category for the third quarter in a row. The company also earned Leader status in Lead Generation, adding to its track record of G2 category leadership and a growing list of industry awards.

G2 is the world's largest and most trusted software and services marketplace. Its quarterly rankings are built on verified reviews from real users, combined with market presence data. Leader status goes to companies that earn consistently high satisfaction ratings from customers while showing strong market presence, which makes the recognition a direct reflection of client results and trust.

"This recognition belongs to our clients and our team," said Paul Griffin, Co-Founder and CEO of The Sales Factory. "You can't buy or market your way to the #2 spot in the world in Outsourced Sales. It comes from real reviews written by real customers, and it validates what we set out to do every day: deliver qualified pipeline, booked meetings, and real revenue growth for the companies that trust us with their business development."

Highlights from the Summer 2026 G2 Reports

- #2 globally in Outsourced Sales, based on customer satisfaction and market presence

- Leader in Lead Generation, continuing the company's category leadership from prior quarters

- Customers consistently praise The Sales Factory for the quality of meetings booked, fast onboarding, transparent communication, and acting as a true extension of their sales teams

"Rankings on G2 reports are based on data provided to us by real software buyers," said Sara Rossio, Chief Product Officer at G2. "Potential buyers know they can trust these insights when researching and selecting software because they're rooted in vetted, verified, and authentic reviews."

The recognition caps a strong stretch for The Sales Factory. A three-time honoree on The Globe and Mail's Canada's Top Growing Companies list, including ranking as the #1 Top Growing Business Services company in 2025, the company continues to expand with operations in Toronto and Tampa serving clients throughout North America and beyond.

To read The Sales Factory's reviews, visit the company's G2 profile.

About The Sales Factory

Founded in Toronto in 2018 by Paul Griffin and Eric Doucet, The Sales Factory is an AI-augmented B2B revenue infrastructure company that designs, builds, and operates complete outbound sales engines for its clients. The company goes beyond supplying leads. It delivers the full infrastructure behind predictable revenue growth, including go-to-market strategy, market research, ideal customer profiling, messaging, multi-channel outreach, their proprietary AI software Pitchpilot.ai and high-caliber on-shore sales talent. Operating in multiple languages across many markets, The Sales Factory works with clients ranging from venture-backed scale-ups to S&P 500 companies and government organizations. A three-time honoree on The Globe and Mail's Canada's Top Growing Companies list (ranking #1 Top Growing Business Services company in 2025), the company runs operations from Toronto and Tampa and serves clients throughout North America and beyond. Learn more at www.thesalesfactory.com.

About G2

G2 is the world's largest and most trusted software marketplace. More than 100 million people a year, including employees at every Fortune 500 company, use G2 to make smarter software decisions based on authentic peer reviews. Learn more at www.g2.com.

SOURCE The Sales Factory

Share this article

EDMONTON, AB, Sept. 9, 2026 /PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Faris El Refaie, a biopharmaceutical leader with 25 years of experience, will join the company as Executive Vice President, Global Commercial, effective September 28, 2026.

In this newly created role, Faris will oversee Aurora's global commercial function, with responsibility for furthering the company's medical cannabis market strategy, aligning its global portfolio, growing customer engagement and accelerating commercial capabilities across Canada, Europe, Australia, New Zealand and other international markets as Aurora expands its global footprint.

"We're beyond excited to welcome Faris to Aurora at such a pivotal time in the company's global growth journey," says Miguel Martin, Executive Chairman and CEO of Aurora. "Faris brings decades of executive leadership in the biopharmaceutical industry, with a particular focus on commercial growth and market leadership, that will no doubt be additive to our global strategy and the company's overall ability to lead. At Aurora, we have built a leading global medical cannabis platform grounded in science, quality and patient care. In this newly created executive role, Faris will continue this momentum by strengthening Aurora's presence in key markets to bring high-quality medical cannabis to more patients around the world."

Faris joins Aurora with extensive experience across highly regulated pharmaceutical organizations, spanning innovative medicines, oncology, specialty care, vaccines and consumer healthcare. He has held progressive leadership roles at JAMP Pharma Group, GSK and AstraZeneca, building deep commercial expertise across global markets including Canada, the U.S., Europe and Asia. Throughout his career, Faris has led commercial transformations, global product strategies and cross-functional teams, giving him the experience and perspective to help Aurora build on its strong foundation and unlock new opportunities across its international medical cannabis business.

Faris' appointment reflects Aurora's continued focus on strengthening its global commercial platform as the Company expands its leadership across established and emerging international medical cannabis markets in service of Aurora's purpose of Opening the World to Cannabis™.

About Aurora

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.

Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Information

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the appointment of a new EVP Global Commercial; plans for the commercial acceleration of the Company's global medical cannabis business; the Company's focus on furthering its medical cannabis market strategy, aligning the Company's global portfolio, growing customer engagement and accelerating commercial capabilities across Canada, Europe, Australia, New Zealand and other international markets; and statements regarding other growth opportunities.

Forward-looking information or statements contained in this news release have been developed based on the Company and its management's good faith assumptions relating to the financial, market, regulatory and other relevant environments that will exist and affect the Company's business and operations in the future. Forward-looking information and statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management at the date the statements are made including, among other things, assumptions about: development costs remaining consistent with budgets; the ability to manage anticipated and unanticipated costs; access to favorable equity and debt capital markets; the ability to raise sufficient capital to advance the business of the Company; favorable operating and economic conditions; political and regulatory stability; obtaining and maintaining all required licenses and permits; receipt of governmental approvals and permits; sustained labour stability; stability in financial and capital goods markets; favorable production levels and costs from the Company's operations; the pricing of various cannabis products; the level of demand for cannabis products; the availability of third-party service providers and other inputs for the Company's operations; and the Company's ability to conduct operations in a safe, efficient, and effective manner. The Company does not give any assurance that the assumptions on which forward-looking information or statements are based will prove to be correct, or that the Company's business or operations will not be affected in any material manner by these or other factors not foreseen or foreseeable by the Company or management or beyond the Company's control. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete construction projects and facilities improvements, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion to revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, and other risks as set out under "Risk Factors" contained in the Annual Information Form dated June 10, 2026 (the "2026 AIF"). Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements. The Company cautions that the list of risks, uncertainties and other factors described in the 2026 AIF is not exhaustive and other factors could also adversely affect its results. Although the Company believes that the expectations conveyed by the forward-looking statements are reasonable based on the information available to the Company on the date hereof, no assurance can be given as to future results, approvals or achievements.

SOURCE Aurora Cannabis Inc.

Share this article